|Articles|April 1, 2013
Preservative-free preparation may improve adherence
Tafluprost 0.0015% is safe, effective and well-tolerated in routine clinical practice
Advertisement
To date, prostaglandin analogues (PGAs) have become the most common medical treatment worldwide to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. PGAs have a strong, sustained and stable IOPlowering effect and a generally well tolerated systemic safety profile.
Tafluprost 0.0015% is the first and only PGA that is available in a preservative-free formulation. We evaluated the efficacy, local tolerability and safety of preservative-free tafluprost 0.0015% (Taflotan) in a routine clinical setting.1
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5







